Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Calgary
$120,000.00
Repurposing a clinically approved safety switch to engineer exhaustion resistant CAR-T cells
EF 2025-26
Résumé
The ability to retrain the immune system to detect and eliminate cancer has revolutionized cancer treatment, particularly through CAR-T cell immunotherapy. CAR-T therapy reprograms a patient's own T cells, the killer cell of the immune system, to recognize and precisely eliminate cancer cells. While revolutionary for some patients, this approach suffers from variable response rates. Gene editing can significantly improve CAR-T cell function; however, low editing efficiencies currently limit its therapeutic applications.
We hypothesize that repurposing inducible caspase 9 (iC9), a safety switch used for cellular therapies, as a selection system for edited cells will achieve therapeutically relevant editing efficiencies (>80%) to enable engineering of superior CAR-T therapies.
To achieve this, iC9 will be inserted into the cells, then selectively inactivated by genome editing, resulting in the death of unedited cells upon iC9 activation. We have established iC9 as a co-selection system, observing up to 4-fold enrichment of genes of interest. Building on these preliminary data, this project focuses on applying the iC9 selection system to enhance gene editing in T cells to improve immunotherapy treatments like CAR-T therapies. This project will 1) demonstrate editing to improve function of human T cells, 2) validate therapeutic benefit in mouse tumor models, and 3) establish temporal control of in vivo editing.
Importantly, the use of iC9 in cellular therapies is approved by Health Canada, eliminating major regulatory barriers to clinical translation, and transforming a common safety feature into a powerful immunotherapy engineering tool. Building on the first phase 1 CAR-T clinical trial at the University of Calgary, successful repurposing of iC9 as a selection system for edited immune cells will enable rapid generation of more robust and cytotoxic CAR-T therapies for clinical translation, ultimately increasing and prolonging overall response rates.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
559818
Name
Curry Jada
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Repurposing a clinically approved safety switch to engineer exhaustion resistant CAR-T cells
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Car-T Therapies; Crispr/Cas9 Technologies; Genome Editing; Immune Cell Engineering; Immunotherapy
Abstract
The ability to retrain the immune system to detect and eliminate cancer has revolutionized cancer treatment, particularly through CAR-T cell immunotherapy. CAR-T therapy reprograms a patient's own T cells, the killer cell of the immune system, to recognize and precisely eliminate cancer cells. While revolutionary for some patients, this approach suffers from variable response rates. Gene editing can significantly improve CAR-T cell function; however, low editing efficiencies currently limit its therapeutic applications.
We hypothesize that repurposing inducible caspase 9 (iC9), a safety switch used for cellular therapies, as a selection system for edited cells will achieve therapeutically relevant editing efficiencies (>80%) to enable engineering of superior CAR-T therapies.
To achieve this, iC9 will be inserted into the cells, then selectively inactivated by genome editing, resulting in the death of unedited cells upon iC9 activation. We have established iC9 as a co-selection system, observing up to 4-fold enrichment of genes of interest. Building on these preliminary data, this project focuses on applying the iC9 selection system to enhance gene editing in T cells to improve immunotherapy treatments like CAR-T therapies. This project will 1) demonstrate editing to improve function of human T cells, 2) validate therapeutic benefit in mouse tumor models, and 3) establish temporal control of in vivo editing.
Importantly, the use of iC9 in cellular therapies is approved by Health Canada, eliminating major regulatory barriers to clinical translation, and transforming a common safety feature into a powerful immunotherapy engineering tool. Building on the first phase 1 CAR-T clinical trial at the University of Calgary, successful repurposing of iC9 as a selection system for edited immune cells will enable rapid generation of more robust and cytotoxic CAR-T therapies for clinical translation, ultimately increasing and prolonging overall response rates.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Curry, Jada
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~